Molecular Devices Inks Deal With Hub Organoids To Advance Automated Intestinal Organoid Screening Technology

Molecular Devices and HUB Organoids collaborate to enable continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition.

Molecular Devices, LLC., a leading provider of high-performance life science solutions, and HUB Organoids (HUB), the pioneer in the field of adult stem cell-derived organoids, announced a strategic collaboration enabling continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition.

Recent AiThority News : Intermap Selected by the U.S. Department of Defense to Demonstrate Advanced AI/ML

Under terms of the agreement, Molecular Devices will license cutting-edge HUB Organoid Technology to work with patient-derived intestinal organoids, expanding Molecular Devices’ 3D biology expertise beyond organoid types like heart and brain. The physiologically-relevant adult stem cell-derived organoids closely resembling human biology, will be used to demonstrate proof of concept for an end-to-end automated workflow that encompasses instrumentation and software analysis.

“Aligning with HUB Organoids supports our mission to fully automate complex protocols that increase efficiency and precision of biologically testing new therapeutics and future medications for patients,” said Susan Murphy, President of Molecular Devices. “HUB’s proven technology has been used to select drugs for Phase 1 clinical trials. Through this collaboration, we will enable the scale and reproducibility that drug hunters need to confidently participate in a new era of drug discovery and development.”

NLP News: Mindsdb Raises $16.5Million From Benchmark to Put Machine Learning Into More Applications

According to HUB, HUB Organoids® can speed up the drug development timeline to about five years, down from the industry’s expected 10- to 15-year bench-to-bedside window. Organoid applications coupled with innovative, automated solutions from Molecular Devices that culture, image, and analyze 3D models repeatably, give researchers an opportunity to screen with more physiologically relevant cell systems in a high-throughput manner to get drugs to market faster.

“With this new license deal, we are bringing together HUB´s world-leading organoid technology with Molecular Devices´ innovative, end-to-end workflow solutions, empowering scientists to increase the throughput for their experiments and tests,” said Bahar Ramezanpour, CBO at HUB. “We believe this partnership will enable scientists to achieve greater scale and reproducibility when working with patient-derived organoids.”

 Latest Aithority Insights : Lion Announces It Will Explore ChatGPT Related AI & NLP Technologies To Empower Digital Program

 [To share your insights with us, please write to sghosh@martechseries.com]